Boldenone
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Boldenone
| |
| Systematic (IUPAC) name | |
| 3-[(8R,9S,10R,13S,14R,17R) -17-hydroxy-10,13-dimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17- dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] propanoic acid | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C19H26O2 |
| Mol. mass | 286.409 g/mol |
| Physical data | |
| Melt. point | 165 °C (329 °F) |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 14 days |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status |
Schedule III (US) |
| Routes | Intramuscular |
|
WikiDoc Resources for Boldenone | |
|
Articles | |
|---|---|
|
Most recent articles on Boldenone | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Boldenone at Clinical Trials.gov Clinical Trials on Boldenone at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Boldenone
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Boldenone Discussion groups on Boldenone Directions to Hospitals Treating Boldenone Risk calculators and risk factors for Boldenone
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Boldenone | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Boldenone (1,4-androstadiene-3-one-17β-ol, available as the undecylenate ester), also known under the trade names Equipoise, Ganabol, Equigan and Ultragan, is an anabolic steroid developed for veterinary use, mostly for treatment of horses. It is not indicated for use in humans in the US and is only available through veterinary clinics.
The activity of boldenone is mainly anabolic, with a low androgenic potency. It has a very long half-life, and can show up on a steroid test for up to 5 months.
Boldenone will increase nitrogen retention, protein synthesis, increases appetite and stimulates the release of erythropoietin in the kidneys.
Because it has similar properties to methandienone (methylated boldenone), it is a favorite for adding strength and size. Boldenone is popular for bulking because it increases the appetite. Boldenone is well known for increasing vascularity.
Boldenone has a low rate of aromatization (about 50% of Testosterone), which means it does not convert to estrogen easily and does not cause very much water retention.
It is easily detectable in blood tests due to its long metabolic half-life. Trace amounts of the drug can easily be detected for months after discontinued use.
Side effects
Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and all the associated progestinic side effects. Boldenone can, however, produce mild androgenic side effects. Oily skin, acne, increased aggression and hair loss are all possible with this compound but rare. Boldenone does reduce to a more potent androgen dihydroboldenone via the 5alpha-reductase enzyme (analogous to the conversion of testosterone to dihydrotestosterone (DHT), however its affinity for this interaction in the human body is low to nonexistent. Suppression of the HPTA, water retention, possible increase in acne and possible conversion to estrogen, high blood pressure are all side effects associated with Boldenone. Boldenone is also known to cause anxiety and flu like symptoms which manifest themselves most acutely in short ester versions like: acetate, and propionate (almost unusable), but which are also present in the enanthate, cypionate, and undecyclenate forms.
References
Anabolic steroids (A14) (trademark names in brackets) | |
|---|---|
| Androstan (carbon 19 present) | Androstadienone • Boldenone undecylenate (Equipoise) • 4-Chlordehydromethyltestosterone (Turinabol) • Clostebol • Desoxymethyltestosterone (Madol) • DHEA • DHT • Drostanolone (Masteron) • Fluoxymesterone (Halotestin) • Furazabol (Miotolan) • Methandrostenolone (Dianabol) • Methenolone • Mesterolone (Proviron) • Methenolone enanthate (Primobolan) • Mestanolone • Norethandrolone • Oxandrolone (Anavar) • Oxymetholone (Anadrol) • Oxymetholone (Anadrol-50) • Quinbolone (Anabolicum Vister) • Stanozolol (Winstrol) • Testosterone |
| Estren (carbon 19 absent) | Ethylestrenol • Mibolerone (Cheque Drops) • Nandrolone (Deca Durabolin) • Norbolethone (Genabol) • Oxabolone cipionate • Tetrahydrogestrinone (The Clear) • Trenbolone (Fina) |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
